InvestorsHub Logo

MinnieM

01/17/17 4:52 PM

#168636 RE: Rdunn88 #168634

History shows Leo has been very careful with dilution while advancing trials. And, financing is always a concern for biotech. Nothing new.

As far as turning down offers, none of us is in a position to know what he has or hasn't done in that regard.





In Reply to 'Rdunn88'
There's been rumors that Leo may of had offers, but is holding out for maximize results... No problem with that, but it does expose them for these types of days... Financing has been a concern.




noretreat

01/17/17 6:09 PM

#168655 RE: Rdunn88 #168634

Financing is THE concern. I've been looking for an improved balance sheet for a long time, and it is keeping me largely on the sidelines despite promising trials.

I've seen this time and again: If you want a decent partner/buyout multiple, strengthen your balance sheet, even if share price suffers. Be positioned to "go it alone" if you have to. If there are dollars available to take you through phase 3, or even through an NDA, you will benefit when it comes to acquisition and/or partnering.

Frankly, I pretty dang sure CTIX' management know this.